NCT00694603View on ClinicalTrials.gov

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Cetuximab

Given intravenously once per week.

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Unity Health Toronto

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Lecia V. Sequist

OTHER

NCT00694603 - Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy | Biotech Hunter | Biotech Hunter